Biolex reports HCV data

Biolex Therapeutics Inc. (Pittsboro, N.C.) presented data from the Phase IIa PLUS trial in 32 HCV patients who had failed prior treatment that showed that 320 and 640 ug Locteron every two weeks plus ribavirin resulted in total severity scores for flu-like symptoms that were 80% and 30% lower, respectively, compared with 1.5 ug/kg weekly PEG-Intron peginterferon alfa-2b plus ribavirin at four weeks. Biolex said anti-viral effects and injection site reactions were comparable among the Locteron and PEG-Intron cohorts. Data from the open-label, U.S. study were presented at the European Association for the Study of the Liver meeting in Copenhagen. ...